Literature DB >> 233764

Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein.

E B Smith1, K M Alexander, I B Massie.   

Abstract

A quantitative assay for fibrin or other insoluble fibrin-like antigens ("fibrin") in small samples of intima is described. Tissue samples were subjected to electrophoresis directly from the intima into an antibody-containing gel to remove and measure fibrinogen and other soluble fibrin reactive antigens (FRA). The residual tissue was then exhaustively incubated with plasmin, and the soluble fragments generated from the insoluble "fibrin" were measured by quantitative immunoelectrophoresis. "Fibrin" accounted for about 2% of the tissue dry weight in normal intima and the ratio fibrinogen/"fibrin" was 1-1.5. In the gelatinous lesions, which seem to be the precursors of fibrous plaques, there was a small increase in "fibrin" but a substantial increase in fibrinogen and low density (LD)-lipoprotein, and the ratio fibrinogen/"fibrin" rose to about 3, which suggests that the increase in "fibrin" is secondary to increased permeation of fibrinogen. At the edges of large plaques there was also a threefold increase in fibrinogen, but "fibrin" increased fivefold, and accounted for 10% of the tissue dry weight. The same high concentration was found in the centres of large fibrous plaques with advanced atheroma lipid. Raised levels of "fibrin" were accompanied by raised levels of fibrinogen in most tissue samples. About 80% of the total soluble FRA could be clotted with thrombin; there was no significant difference between normal intima and lesions, and the proportion clotted was not related to "fibrin" content.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 233764     DOI: 10.1016/0021-9150(76)90116-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Fibrinogen/fibrin in atherogenesis.

Authors:  E B Smith; W D Thompson; L Crosbie; C M Stirk
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 2.  Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.

Authors:  F C Schoebel; T W Jax; Y Fischer; B E Strauer; M Leschke
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 3.  The vascular endothelium-pathobiologic significance.

Authors:  G Thorgeirsson; A L Robertson
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

4.  A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.

Authors:  D K Galanakis; B Ghebrehiwet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

5.  The influence of type 2 diabetes on fibrin structure and function.

Authors:  E J Dunn; R A S Ariëns; P J Grant
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

6.  Molecular interactions in human atherosclerotic plaques.

Authors:  E B Smith
Journal:  Am J Pathol       Date:  1977-03       Impact factor: 4.307

7.  Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas.

Authors:  R Valenzuela; J R Shainoff; P M DiBello; D A Urbanic; J M Anderson; G R Matsueda; B J Kudryk
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

8.  Activation of coagulation releases endothelial cell mitogens.

Authors:  C Gajdusek; S Carbon; R Ross; P Nawroth; D Stern
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.